secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001193125-24-253143
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Q3 net loss $31.2M (-$0.37/sh); COVID-19 Phase 3 fails, HCV topline Dec 2024
--------------------------------------------------------------------------------

- Net loss $31.2M ($0.37 diluted EPS) vs $33.1M loss ($0.40) YoY; cash $482.8M at Sept 30.
- Phase 3 SUNRISE-3 COVID-19 trial missed primary endpoint; no regulatory path pursued.
- Phase 2 HCV study (n=275) topline SVR12 results expected early Dec 2024; FDA End-of-Phase 2 meeting planned Q1 2025.
- R&D spend $26.2M, down $2.0M YoY due to lower COVID spend offset by higher HCV costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312524253143/0001193125-24-253143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312524253143/d841992d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-253143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer